Cerner Corporation and NextCode Health have backed a series B round that will fund the launch of Claritas' new sequencing test for paediatric disorders.
Claritas Genomics, a US-based company developing sequencing tests for genetic paediatric disorders, raised $15m on Monday from a series B round led by life sciences company NextCode Health.
The round also included healthcare IT company Cerner Corporation, Boston Children’s Hospital and Cincinnati Children’s Hospital Medical Center. All three previously invested an undisclosed amount in the company’s series A round in 2013.
Claritas and NextCode Health formed a partnership last month to harness NextCode’s big data analysis technology in order to…
